<i>HER2</i> Evaluation and Its Impact on Breast Cancer Treatment Decisions Public Health Genomics 2012;15:1–10 - DOI:10.1159/000325746 Fig. 1. Rate of HER2 testing at KPNW from 1998 to 2007. The solid lines correspond to patients diagnosed with invasive breast cancer with Medicare/Medicaid insurance (diamonds) or with other insurance (circles), and the dashed lines correspond to patients diagnosed with ductal carcinoma in situ or noninvasive breast cancer. © 2011 S. Karger AG, Basel - CC BY-NC 3.0